For US residents only.

How Treatment May Help

TAFINLAR + MEKINIST

How TAFINLAR + MEKINIST may help BRAF V600E metastatic NSCLC

In a clinical trial, TAFINLAR® (dabrafenib) capsules + MEKINIST® (trametinib) tablets was shown to help shrink or slow the growth of tumors in untreated and previously treated patients. The overall response rate measures the size or number of tumors. This number includes patients whose tumors became smaller or fewer in number (which is called a partial response), and patients whose tumors disappeared completely (which is called a complete response). Complete response is not the same as a cure.

Overall Response Rate

Untreated

A total of 61% of 36 untreated patients achieved a response with TAFINLAR + MEKINIST. A total of 3% of untreated patients had a complete response and 58% had a partial response. As measured in a follow-up evaluation of the same trial, a total of 64% of untreated patients achieved a response with TAFINLAR + MEKINIST. A total of 6% of untreated patients had a complete response and 58% had a partial response.

Previously Treated

A total of 63% of 57 previously treated patients achieved a response with TAFINLAR + MEKINIST. Of these responders, 4% had a complete response and 60% of patients had a partial response.

With TAFINLAR + MEKINIST, 6 out of 10 responders had an antitumor response that was 6 months or longer

Duration of Response

Duration of response is a measure of how long a treatment can keep tumors from growing again after a response has first been detected.

Duration of Response in Previously Treated Patients

The median (or midpoint) duration of response for patients who were previously treated was 12.6 months. This means that half of the patients who responded to treatment continued to respond longer than 12.6 months and half responded less than 12.6 months.

Duration of Response in Untreated Patients

During the initial trial evaluation, the median (or midpoint) duration of response for patients who have never been treated could not be determined. As measured in a follow-up evaluation of the same trial, the median duration of response for these patients was 15.2 months. This means that half of the patients who responded to treatment continued to respond longer than 15.2 months and half went shorter than 15.2 months.

Untreated

Of the 22 untreated patients who had a response with TAFINLAR + MEKINIST, 59% had a duration of response of 6 months or longer before their disease got worse.

Previously Treated

Of the 36 previously treated patients who had a response with TAFINLAR + MEKINIST, 64% had a duration of response of 6 months or longer before their disease got worse.